Company profile for Epirium

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical stage biopharmaceutical company that has uncovered unique insights into the biology of mitochondrial biogenesis and function, leading to an advanced understanding of its pleotropic clinical effect in disease. These findings have led to the discovery of a novel, previously undescribed pharmacological approach to the treatment of diseases characterized by deficits in these pathways. We have identified and estab...
We are a clinical stage biopharmaceutical company that has uncovered unique insights into the biology of mitochondrial biogenesis and function, leading to an advanced understanding of its pleotropic clinical effect in disease. These findings have led to the discovery of a novel, previously undescribed pharmacological approach to the treatment of diseases characterized by deficits in these pathways. We have identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4110 Campus Point Court San Diego, CA 92121
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251117333357/en/Epirium-Bio-Presented-Positive-Phase-1-Safety-Pharmacokinetics-and-Pharmacodynamics-Data-for-MF-300-Supporting-its-Role-in-Muscle-Health-as-a-Late-Breaker-at-the-Gerontological-Society-of-America-Annual-Scientific-Meeting-2025

BUSINESSWIRE
17 Nov 2025

https://www.businesswire.com/news/home/20250924461947/en/Epirium-Bio-Announces-Positive-Phase-1-Clinical-Trial-Results-Evaluating-MF-300-in-Healthy-Volunteers-A-First-In-Class-Oral-15-PGDH-Enzyme-Inhibitor-For-the-Treatment-of-Sarcopenia

BUSINESSWIRE
24 Sep 2025

https://www.businesswire.com/news/home/20250721709030/en/Epirium-Bio-Completes-Dosing-in-First-In-Human-Phase-1-Clinical-Trial-Evaluating-MF-300-A-First-In-Class-Oral-15-PGDH-Enzyme-Inhibitor-For-the-Treatment-of-Sarcopenia

BUSINESSWIRE
21 Jul 2025

https://www.businesswire.com/news/home/20250130038128/en

BUSINESSWIRE
30 Jan 2025

https://www.businesswire.com/news/home/20241223801377/en

BUSINESSWIRE
23 Dec 2024

https://www.businesswire.com/news/home/20241113984372/en

BUSINESSWIRE
13 Nov 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty